• Je něco špatně v tomto záznamu ?

Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands

M. Modoux, N. Rolhion, JH. Lefevre, C. Oeuvray, P. Nádvorník, P. Illes, P. Emond, Y. Parc, S. Mani, Z. Dvorak, H. Sokol

. 2022 ; 14 (1) : 2105637. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025479

Aryl hydrocarbon receptor (AhR) is a critical player in the crosstalk between the gut microbiota and its host. However, factors regulating AhR within the gut, which is a complex metabolomic environment, are poorly understood. This study investigates the effect of a combination of metabolites on the activation mechanism of AhR. AhR activity was evaluated using both a luciferase reporter system and mRNA levels of AhR target genes on human cell lines and human colonic explants. AhR activation was studied by radioligand-binding assay, nuclear translocation of AhR by immuofluorescence and protein co-immunoprecipitation of AhR with ARNT. Indirect activation of AhR was evaluated using several tests and inhibitors. The promoter of the target gene CYP1A1 was studied both by chromatin immunoprecipitation and by using an histone deacetylase HDAC inhibitor (iHDAC). Short-chain fatty acids, and butyrate in particular, enhance AhR activity mediated by endogenous tryptophan metabolites without binding to the receptor. This effect was confirmed in human intestinal explants and did not rely on activation of receptors targeted by SCFAs, inhibition of AhR degradation or clearance of its ligands. Butyrate acted directly on AhR target gene promoter to reshape chromatin through iHDAC activity. Our findings revealed that butyrate is not an AhR ligand but acts as iHDAC leading to an increase recruitment of AhR to the target gene promoter in the presence of tryptophan-derived AhR agonists. These data contribute to a novel understanding of the complex regulation of AhR activation by gut microbiota-derived metabolites.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025479
003      
CZ-PrNML
005      
20221031100842.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/19490976.2022.2105637 $2 doi
035    __
$a (PubMed)35895845
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Modoux, Morgane $u Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, France $u Paris Centre for Microbiome Medicine (PaCeMM) FHU, Paris, France
245    10
$a Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands / $c M. Modoux, N. Rolhion, JH. Lefevre, C. Oeuvray, P. Nádvorník, P. Illes, P. Emond, Y. Parc, S. Mani, Z. Dvorak, H. Sokol
520    9_
$a Aryl hydrocarbon receptor (AhR) is a critical player in the crosstalk between the gut microbiota and its host. However, factors regulating AhR within the gut, which is a complex metabolomic environment, are poorly understood. This study investigates the effect of a combination of metabolites on the activation mechanism of AhR. AhR activity was evaluated using both a luciferase reporter system and mRNA levels of AhR target genes on human cell lines and human colonic explants. AhR activation was studied by radioligand-binding assay, nuclear translocation of AhR by immuofluorescence and protein co-immunoprecipitation of AhR with ARNT. Indirect activation of AhR was evaluated using several tests and inhibitors. The promoter of the target gene CYP1A1 was studied both by chromatin immunoprecipitation and by using an histone deacetylase HDAC inhibitor (iHDAC). Short-chain fatty acids, and butyrate in particular, enhance AhR activity mediated by endogenous tryptophan metabolites without binding to the receptor. This effect was confirmed in human intestinal explants and did not rely on activation of receptors targeted by SCFAs, inhibition of AhR degradation or clearance of its ligands. Butyrate acted directly on AhR target gene promoter to reshape chromatin through iHDAC activity. Our findings revealed that butyrate is not an AhR ligand but acts as iHDAC leading to an increase recruitment of AhR to the target gene promoter in the presence of tryptophan-derived AhR agonists. These data contribute to a novel understanding of the complex regulation of AhR activation by gut microbiota-derived metabolites.
650    _2
$a butyráty $x farmakologie $7 D002087
650    12
$a střevní mikroflóra $7 D000069196
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    12
$a receptory aromatických uhlovodíků $x genetika $x metabolismus $7 D018336
650    _2
$a tryptofan $7 D014364
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rolhion, Nathalie $u Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, France $u Paris Centre for Microbiome Medicine (PaCeMM) FHU, Paris, France
700    1_
$a Lefevre, Jeremie H $u Paris Centre for Microbiome Medicine (PaCeMM) FHU, Paris, France $u Sorbonne Université, Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France
700    1_
$a Oeuvray, Cyriane $u Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, France $u Paris Centre for Microbiome Medicine (PaCeMM) FHU, Paris, France
700    1_
$a Nádvorník, Petr $u Departments of Cell Biology and Genetics, Palacký University, Olomouc, Czech Republic
700    1_
$a Illes, Peter $u Departments of Cell Biology and Genetics, Palacký University, Olomouc, Czech Republic
700    1_
$a Emond, Patrick $u UMR 1253, iBrain, Université de Tours, Inserm, Tours, Centre-Val de Loire, France
700    1_
$a Parc, Yann $u Sorbonne Université, Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France
700    1_
$a Mani, Sridhar $u Departments of Molecular Pharmacology, Genetics and Medicine, Albert Einstein College of Medicine, Bronx, NY, USA
700    1_
$a Dvorak, Zdenek $u Departments of Cell Biology and Genetics, Palacký University, Olomouc, Czech Republic
700    1_
$a Sokol, Harry $u Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, France $u Paris Centre for Microbiome Medicine (PaCeMM) FHU, Paris, France $u INRAe, UMR1319 Micalis & AgroParisTech, Jouy en Josas, France $1 https://orcid.org/0000000229141822
773    0_
$w MED00175586 $t Gut microbes $x 1949-0984 $g Roč. 14, č. 1 (2022), s. 2105637
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35895845 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100838 $b ABA008
999    __
$a ok $b bmc $g 1854946 $s 1176769
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 1 $d 2105637 $e - $i 1949-0984 $m Gut microbes $n Gut microbes $x MED00175586
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

    Možnosti archivace